Skip to main content
Janette Greenhalgh

Dr Janette Greenhalgh
PhD, PGCE

Contact

Janette.Greenhalgh@liverpool.ac.uk

+44 (0)151 795 5443

Publications

What type of publication do you want to show?

2024

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.

Fleeman, N., Houten, R., Nevitt, S., Mahon, J., Beale, S., Boland, A., . . . Waddell, T. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.. Health technology assessment (Winchester, England), 28(49), 1-190. doi:10.3310/trrm4238

DOI
10.3310/trrm4238
Journal article

2023

Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]

Greenhalgh, J., Mahon, J., Houten, R., Edwards, K., Donegan, S., Boland, A., . . . Mcentee, J. (2023). Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]: Upadacitinib for treating moderately to severely active ulcerative colitis[ID3953]. Retrieved from https://www.fundingawards.nihr.ac.uk/award/NIHR135585

Report

Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child

Khanom, S., Adab, N., Bluett-Duncan, M., Clayton-Smith, J., Christensen, J., Edwards, K., . . . Bromley, R. (2023). Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child. In NEUROTOXICOLOGY AND TERATOLOGY Vol. 98. doi:10.1016/j.ntt.2023.107243

DOI
10.1016/j.ntt.2023.107243
Conference Paper

Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]

Greenhalgh, J., Mahon, J., Bryning, S., Chaplin, M., Beale, S., Boland, A., . . . Basu, B. (2023). Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]. Retrieved from https://www.nice.org.uk/guidance/gid-ta10920/documents/committee-papers

Report

2021

Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]

Bresnahan, R., Houten, R., Mahon, J., Beale, S., Nevitt, S., Greenhalgh, J., . . . Gandhi, S. (2021). Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/

Report

Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]

Greenhalgh, J., Mahon, J., Nevitt, S., Bresnahan, R., Boland, A., Beale, S., . . . Boon, C. (2021). Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]: Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/

Report

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Houten, R., Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., . . . McEntee, J. (2021). Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 5(1), 13-22. doi:10.1007/s41669-020-00206-x

DOI
10.1007/s41669-020-00206-x
Journal article

2020

Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]

Bresnahan, R., Mahon, J., Nevitt, S., Beale, S., Boland, A., Greenhalgh, J., . . . Campbell, L. (2020). Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]: Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/

Report

Sapropterin dihydrochloride for treating phenylketonuria [ID1475]

Greenhalgh, J., James, M., Nevitt, S., Bresnahan, R., Beale, S., Boland, A., . . . Schwan, B. (2020). Sapropterin dihydrochloride for treating phenylketonuria [ID1475]: Sapropterin dihydrochloride for treating phenylketonuria [ID1475]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/

Report

Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]

Greenhalgh, J., Lambe, T., Mahon, J., Nevitt, S., Edwards, K., Bresnahan, R., . . . Green, J. (2020). Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]: Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/

Report

Midostaurin for treating advanced systemic mastocytosis [ID1573]

Greenhalgh, J., Lambe, T., Nevitt, S., Mahon, J., Boland, A., Beale, S., . . . Moonim, M. (2020). Midostaurin for treating advanced systemic mastocytosis [ID1573]: Midostaurin for treating advanced systemic mastocytosis [ID1573]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/

Report

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/

Report

Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation

Duarte, R., Stainthorpe, A., Greenhalgh, J., Richardson, M., Nevitt, S., Mahon, J., . . . Takwoingi, Y. (2020). Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(3), 1-+. doi:10.3310/hta24030

DOI
10.3310/hta24030
Journal article

2019

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7

DOI
10.1186/s12885-019-6369-7
Journal article

Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation

Duarte, R., Stainthorpe, A., Mahon, J., Greenhalgh, J., Richardson, M., Nevitt, S., . . . Takwoingi, Y. (2019). Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation. PLOS ONE, 14(12). doi:10.1371/journal.pone.0226671

DOI
10.1371/journal.pone.0226671
Journal article

Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck

Greenhalgh, J., Mahon, J., Chaplin, M., Nevitt, S., Boland, A., Beale, S., . . . Shaw, R. (2019). Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck: Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (17/56/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10181/documents/committee-papers

Report

Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer

Greenhalgh, J., Mahon, J., Chaplin, M., Beale, S., Boland, A., Lambe, T., . . . Palmieri, C. (2019). Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer: Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer (128748). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10433/documents/committee-papers

Report

2018

Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma

Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Danson, S. (2018). Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (17/109/14). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta562/documents/committee-papers

Report

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1

DOI
10.1007/s40273-018-0646-1
Journal article

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence

Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Marshall, E. (2018). Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (17/109/17). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta553/documents/committee-papers

Report

2017

Cladribine for the treatment of relapsing-remitting multiple sclerosis

Duarte, R., Mahon, J., Nevitt, S., Greenhalgh, J., Boland, A., Beale, S., . . . Mcentee, J. (n.d.). Cladribine for the treatment of relapsing-remitting multiple sclerosis (ID64). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta493/documents/committee-papers

Report

Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer

Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers

Report

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

Greenhalgh, J., Bagust, A., Stainthorpe, A., Chaplin, M., Boland, A., De Sousa Rego Vieira Duarte, R., . . . Palmer, D. (2017). Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (14/90/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers

Report

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy

Greenhalgh, J. (n.d.). Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy (ID970). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta520/documents/committee-papers

Report

VP177 Older People With Cancer: To Treat Or Not To Treat With Chemotherapy?

Boland, A., Pilkington, G., Greenhalgh, J., & Dickson, R. (2017). VP177 Older People With Cancer: To Treat Or Not To Treat With Chemotherapy?. International Journal of Technology Assessment in Health Care, 33(S1), 232-233. doi:10.1017/s0266462317004123

DOI
10.1017/s0266462317004123
Journal article

2016

Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Weston, J., Bromley, R., Jackson, C. F., Adab, N., Clayton-Smith, J., Greenhalgh, J., . . . Marson, A. G. (2016). Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.. The Cochrane database of systematic reviews, 11. doi:10.1002/14651858.CD010224.pub2

DOI
10.1002/14651858.CD010224.pub2
Journal article

Nitrous oxide-based versus nitrous oxide-free general anaesthesia and accidental awareness during general anaesthesia in surgical patients

Hounsome, J., Nicholson, A., Greenhalgh, J., Cook, T. M., Smith, A. F., & Lewis, S. R. (2016). Nitrous oxide-based versus nitrous oxide-free general anaesthesia and accidental awareness during general anaesthesia in surgical patients. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD011052.pub2

DOI
10.1002/14651858.CD011052.pub2
Journal article

Everolimus in combination with an aromatase inhibitor for the treatment of advanced or metastatic HER2 negative, oestrogen receptor positive breast cancer after prior endocrine therapy

Greenhalgh, J. (n.d.). Everolimus in combination with an aromatase inhibitor for the treatment of advanced or metastatic HER2 negative, oestrogen receptor positive breast cancer after prior endocrine therapy (ID1011). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta421/documents/committee-papers

Report

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer

Greenhalgh, J., Dwan, K., Boland, A., Bates, V., Vecchio, F., Dundar, Y., . . . Green, J. A. (2016). First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010383.pub2

DOI
10.1002/14651858.CD010383.pub2
Journal article

Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma

Greenhalgh, J., Mahon, J., Beale, S., Boland, A., Krishan, A., Chaplin, M., . . . Steven, N. (2016). Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (12/50/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta396/history

Report

Talimogene laherparepvec for treating metastatic melanoma

Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2

Report

2015

Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Withdrawn Paper. Art. no. CD004587)

Hockenhull, J., Greenhalgh, J., Dickson, R. C., Ricciardi, M., & Patel, A. (2015). Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Withdrawn Paper. Art. no. CD004587). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). Retrieved from https://www.webofscience.com/

Journal article

Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab

Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/

Report

Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab

Greenhalgh, J., Mahon, J., Chaplin, M., Krishan, A., Aslam, R., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab: Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab (14/177/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/TA366/documents/committee-papers

Report

2014

First-Line Treatment of Advanced Epidermal Growth Factor Receptor (Egfr) Mutation Positive (M+) Non-Squamous Non-Small Cell (Nsclc) Lung Cancer – a Cochrane Collaboration Meta-Analysis

Green, J. A., Dwan, K., Bates, V., Boland, A., Jain, P., & Greenhalgh, J. (2014). First-Line Treatment of Advanced Epidermal Growth Factor Receptor (Egfr) Mutation Positive (M+) Non-Squamous Non-Small Cell (Nsclc) Lung Cancer – a Cochrane Collaboration Meta-Analysis. Annals of Oncology, 25, iv449. doi:10.1093/annonc/mdu349.55

DOI
10.1093/annonc/mdu349.55
Journal article

The role of reading on the health and well-being of people with neurological conditions: a systematic review

Latchem, J. M., & Greenhalgh, J. (2014). The role of reading on the health and well-being of people with neurological conditions: a systematic review. AGING & MENTAL HEALTH, 18(6), 731-744. doi:10.1080/13607863.2013.875125

DOI
10.1080/13607863.2013.875125
Journal article

META-ANALYSIS OF NEURODEVELOPMENTAL OUTCOME FOLLOWING PRENATAL EXPOSURE TO ANTIEPILEPTIC DRUGS

Bromley, R. L., Pulman, J. L., Adab, N., Sanniti, A., Greenhalgh, J., McKay, A., . . . Marson, A. G. (2014). META-ANALYSIS OF NEURODEVELOPMENTAL OUTCOME FOLLOWING PRENATAL EXPOSURE TO ANTIEPILEPTIC DRUGS. In EPILEPSIA Vol. 55 (pp. 31). Retrieved from https://www.webofscience.com/

Conference Paper

2013

1181 – Short-term management of agitation associated with psychotic or bipolar disorders: a systematic review

Dundar, Y., & Greenhalgh, J. (2013). 1181 – Short-term management of agitation associated with psychotic or bipolar disorders: a systematic review. European Psychiatry, 28, 1. doi:10.1016/s0924-9338(13)76266-7

DOI
10.1016/s0924-9338(13)76266-7
Journal article

Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review

Dundar, Y., Dwan, K., & Greenhalgh, J. (2013). Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review. In European Congress of Psychiatry (pp. 1). Nice: EPA.

Conference Paper

2012

The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation

Cherry, M. G., Greenhalgh, J., Osipenko, L., Venkatachalam, M., Boland, A., Dundar, Y., . . . Rees, D. C. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 16(43), 1-+. Retrieved from https://www.webofscience.com/

Journal article

Treatment for epilepsy in pregnancy: congenital malformation outcomes in the child

Pulman, J., Bromley, R., Adab, N., Greenhalgh, J., McKay, A. J., Tudur Smith, C., . . . Marson, A. G. (n.d.). Treatment for epilepsy in pregnancy: congenital malformation outcomes in the child. In J. Pulman (Ed.). John Wiley & Sons, Ltd. doi:10.1002/14651858.cd010224

DOI
10.1002/14651858.cd010224
Chapter

Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child

Bromley, R., Pulman, J., Adab, N., Greenhalgh, J., Dickson, R. C., McKay, A. J., . . . Marson, A. G. (n.d.). Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. doi:10.1002/14651858.cd010236

DOI
10.1002/14651858.cd010236
Journal article

2011

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis

Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(31), 1-+. doi:10.3310/hta15310

DOI
10.3310/hta15310
Journal article

Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.

Horne, P. J., Greenhalgh, J., Erjavec, M., Lowe, C. F., Viktor, S., & Whitaker, C. J. (2011). Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.. Appetite, 56(2), 375-385. doi:10.1016/j.appet.2010.11.146

DOI
10.1016/j.appet.2010.11.146
Journal article

'Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.'

Horne, P. J., Greenhalgh, J., Erjavec, M., Lowe, C. F., Viktor, S., & Whitaker, C. J. (2011). 'Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.'. Appetite, 56(2), 375-385. doi:10.1016/j.appet.2010

DOI
10.1016/j.appet.2010
Journal article

2010

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer

Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 33-39. doi:10.3310/hta14suppl2-05

DOI
10.3310/hta14suppl2-05
Journal article

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer

Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 1), 47-53. doi:10.3310/hta14suppl1-07

DOI
10.3310/hta14suppl1-07
Journal article

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention

Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1), 31-38. doi:10.3310/hta14suppl1-05

DOI
10.3310/hta14suppl1-05
Journal article

Biofeedback for hypertension: a systematic review.

Greenhalgh, J., Dickson, R., & Dundar, Y. (2010). Biofeedback for hypertension: a systematic review.. Journal of hypertension, 28(4), 644-652. doi:10.1097/hjh.0b013e3283370e20

DOI
10.1097/hjh.0b013e3283370e20
Journal article

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention

Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05

DOI
10.3310/hta14suppl1/05
Journal article

2009

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (n.d.). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment, 13(Suppl 3), 49-54. doi:10.3310/hta13suppl3-08

DOI
10.3310/hta13suppl3-08
Journal article

The effects of biofeedback for the treatment of essential hypertension: a systematic review.

Greenhalgh, J., Dickson, R., & Dundar, Y. (2009). The effects of biofeedback for the treatment of essential hypertension: a systematic review.. Health technology assessment (Winchester, England), 13(46), 1-104. doi:10.3310/hta13460

DOI
10.3310/hta13460
Journal article

Rituximab for the treatment of rheumatoid arthritis

Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (n.d.). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment, 13(Suppl 2), 23-29. doi:10.3310/hta13suppl2-04

DOI
10.3310/hta13suppl2-04
Journal article

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation

McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010

DOI
10.3310/hta13010
Journal article